SCHEMBL20679889

SCHEMBL20679889

O=S(=O)(Cc1cccnc1)c1nccs1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.41
NR1H3 Q13133 1/20 0.41
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
VNN1 O95497 1/20 0.40
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
MAPK8 P45983 1/20 0.39
CYP2C19 P33261 2/20 0.38
SLC40A1 Q9NP59 1/20 0.38
CHRNA7 P36544 1/20 0.38
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20679918 0.81 NAMPT (0.46) LMNASMN1; SMN2CYP1A2CYP2D6CYP2C19
SCHEMBL28240365 0.73 MRGPRX4 (0.44) HTTSMN1; SMN2
SCHEMBL6182721 0.73 LOXL2 (0.40) ALDH1A1
SCHEMBL27468836 0.73 CYP1A2 (0.52) CYP2A6LMNASMN1; SMN2NAPRTCYP1A2
SCHEMBL14594945 0.72 TBXAS1 (0.51) NAPRTCYP2C9
SCHEMBL8796833 0.72 NAMPT (0.32) MAPK8SLC40A1
SCHEMBL3511229 0.72 CYP2C19 (0.40) CYP1A2CYP2D6CYP2C19SLC40A1ALDH1A1
SCHEMBL1457306 0.70 NAPRT (0.48) CYP2A6NAPRTCYP1A2CYP2D6CYP2C19
SCHEMBL29493165 0.70 CA2 (0.57) CYP2A6NAPRTCYP1A2CYP2D6CHRNA7
SCHEMBL1271313 0.70 NAPRT (0.48) CYP2A6NAPRTCYP1A2CYP2D6CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689354-B2 Aminoazole derivative TEIJIN PHARMA LIMITED (JP) 2020-06-23 US disclosed
US-20190031628-A1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2019-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689354-B2 Aminoazole derivative AR, NR3C2, NR5A1 CYP2A6 1023/4885NR1H3 37/4885ADORA2A 1065/4885
US-20190031628-A1 AMINOAZOLE DERIVATIVE AR, NR3C2, NR5A1 CYP2A6 1023/4885NR1H3 37/4885ADORA2A 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.